- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01001806
A Comparison of Peak Aqueous Penetration of Acuvail (Ketorolac 0.45%), Xibrom (Bromfenac 0.09%), and Nevanac (Nepafenac 0.1%)in Patients Undergoing Phacoemulsification
August 26, 2011 updated by: Frank A. Bucci, Jr., M.D.
A Comparison of Peak Aqueous Penetration of Acuvail, Xibrom, and Nevanac in Patients Undergoing Phacoemulsification
Approximately 126 subjects scheduled to undergo cataract surgery by phacoemulsification, will be randomized in an even allocation (1:1:1) to either Acuvail, Xibrom, or Nevanac.
Subjects will be instructed to begin dosing the study medication in the operative eye the day before surgery and continue dosing on the day of surgery.
Beginning one hour before surgery, 1 drop of study medication will be instilled by operating room staff approximately every 15 minutes for a total of 3 doses.
At the designated time a paracentesis will be performed at the start of the cataract procedure and at least 0.15 cc of aqueous humor will be collected.
The sample will be immediately stored on dry ice and shipped to a laboratory for analysis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
126
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Pennsylvania
-
Wilkes-Barre, Pennsylvania, United States, 18702
- Bucci Laser Vision Institute
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects must be 18 years of age or older.
- Scheduled for cataract surgery by phacoemulsification.
- Subject must be willing to comply with all study requirements and be willing to give informed consent.
Exclusion Criteria:
- Any subject that has a history of uveitis or active iritis.
- Subject can have no previous eye surgery, with the exception of refractive surgery, but not within 6 months.
- No ocular use of prostaglandins within 2 weeks of surgery.
- Use of oral, injectable or topical ophthalmic steroids, nonsteroidal anti-inflammatory (NSAIDS) or immunosuppressants within 14 days prior to surgery.
- Contraindications to NSAIDS.
- Active ocular infection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Acuvail
Acuvail to be given preoperatively.
One drop 2 times daily (BID), 1 day pre op and day of surgery 3 doses prior to surgery
|
One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
Other Names:
|
Active Comparator: Xibrom
Xibrom to be given 1 drop 2 times daily (BID) the day before surgery and 3 doses the day of surgery prior to surgery
|
One day pre operative 1 drop BID then 3 doses pre op day of surgery
Other Names:
|
Active Comparator: Nevanac
One day before surgery 1 drop 2 times daily (BID), then 3 doses the day of surgery
|
One drop BID, 1 day pre operative and then 3 doses the day of surgery
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Peak Aqueous Penetration
Time Frame: day 4 of treatment
|
day 4 of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Frank A Bucci, Jr.,, MD, Bucci Laser Vision Institute
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
December 1, 2009
Study Completion (Actual)
January 1, 2010
Study Registration Dates
First Submitted
October 23, 2009
First Submitted That Met QC Criteria
October 26, 2009
First Posted (Estimate)
October 27, 2009
Study Record Updates
Last Update Posted (Estimate)
October 3, 2011
Last Update Submitted That Met QC Criteria
August 26, 2011
Last Verified
August 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Eye Diseases
- Lens Diseases
- Cataract
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ketorolac
- Bromfenac
- Ketorolac Tromethamine
- Nepafenac
Other Study ID Numbers
- 2009-0199
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataracts
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruiting
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruiting
-
Johnson & Johnson Surgical Vision, Inc.Active, not recruitingCataractsUnited States
-
Johnson & Johnson Surgical Vision, Inc.Completed
-
Medical University of South CarolinaTerminated
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Alcon ResearchCompleted
-
Medical University of ViennaCompleted
Clinical Trials on Ketorolac Tromethamine 0.45%
-
Bucci Laser Vision InstituteAllerganCompletedPost Operative Anterior Chamber Inflammation (Flare)United States
-
University of MalayaCompletedDiabetes Mellitus | Cystoid Macular Edema, PostoperativeMalaysia
-
Oman Medical Speciality BoardCompletedAcute Renal ColicOman
-
Darnitsa Pharmaceutical CompanyCompleted
-
William Beaumont Army Medical CenterCompletedMusculoskeletal Pain | Analgesia | Adverse EventUnited States
-
Queen's UniversityCompleted
-
Seattle Children's HospitalUniversity of WashingtonCompletedPostoperative Pain in InfantsUnited States
-
Université Catholique de LouvainAnticancer Fund, BelgiumCompletedCurative Breast Cancer Surgery | Inflammatory Positive/Negative Status | Pre Surgical Incision AdministrationBelgium
-
Beth Israel Deaconess Medical CenterSociety for Obstetric Anesthesia and PerinatologyActive, not recruitingPostoperative Pain | Postpartum Hemorrhage | Blood Loss, Postoperative | Analgesia, Obstetrical | Coagulation Defect; Postpartum | Nonsteroidals (NSAIDs)Toxicity | Ketorolac Adverse ReactionUnited States
-
New Mexico Cancer Care AllianceCompletedOvarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity CancerUnited States